AtkinsonMA, EisenbarthGS, MichelsAW: Type 1 diabetes. Lancet, 2014; 383:69–82.
2.
ZieglerAG, RewersM, SimellO, et al.: Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA, 2013; 309:2473–2479.
3.
BingleyPJ, WilliamsAJ, ColmanPG, et al.: Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories. Clin Trials, 2010; 7(1 Suppl):S56–S64.
4.
TornC, MuellerPW, SchlosserM, et al.: Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia, 2008; 51:846–852.
5.
LampasonaV, SchlosserM, MuellerPW, et al.: Diabetes Antibody Standardization Program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem, 2011; 57:1693–1702.
6.
SchlosserM, MuellerPW, TornC, et al.: Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia, 2010; 53:2611–2620.
7.
BingleyPJ, RafkinLE, MathesonD, et al.: Use of dried capillary blood sampling for islet autoantibody screening in relatives: a feasibility study. Diabetes Technol Ther, 2015; 17:867–871.
8.
MahonJL, SosenkoJM, Rafkin-MervisL, et al.: The TrialNet natural history study of the development of type 1 diabetes: objectives, design, and initial results. Pediatr Diabetes, 2009; 10:97–104.
9.
BazzigaluppiE, BonfantiR, BingleyPJ, et al.: Capillary whole blood measurement of islet autoantibodies. Diabetes Care, 1999; 22:275–279.
10.
SteckAK, JohnsonK, BarrigaKJ, et al.: Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: Diabetes Autoimmunity Study in the Young. Diabetes Care, 2011; 34:1397–1399.
11.
SimellS, HoppuS, SimellT, et al.: Age at development of type 1 diabetes and celiac disease-associated antibodies and clinical disease in genetically susceptible children observed from birth. Diabetes Care, 2010; 33:774–779.
12.
BonifacioE, ZieglerAG, KlingensmithG, et al.: Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA, 2015; 313:1541–1549.
13.
SkylerJS, KrischerJP, WolfsdorfJ, et al.: Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial—Type 1. Diabetes Care, 2005; 28:1068–1076.
14.
BarkerJM, GoehrigSH, BarrigaK, et al.: Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care, 2004; 27:1399–1404.
15.
SimmonsK, MichelsA: Is it time to screen the general population for type 1 diabetes? U.S. Endocrinology, 2015; 11:10–16.
16.
YuL, MiaoD, ScrimgeourL, et al.: Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes, 2012; 61:179–186.
17.
YuL, DongF, MiaoD, et al.: Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care, 2013; 36:2266–2270.
18.
MiaoD, SteckAK, ZhangLet al.: Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk. Diabetes Technol Ther, 2015; 17:119–127.
19.
GesualdoPD, BautistaKA, WaughKC, et al.: Feasibility of screening for T1D and celiac disease in a pediatric clinic setting. Pediatr Diabetes. 2015 August 6 [Epub ahead of print]. doi: 10.1111/pedi.12301.
20.
InselRA, DunneJL, ZieglerAG: General population screening for type 1 diabetes: has its time come?. Curr Opin Endocrinol Diabetes Obes, 2015; 22:270–276.
